Cell therapy weekly: US FDA fast tracks a novel investigational cell therapy for Type 1 diabetes

This week: the US FDA has granted Fast Track Designation to VX-880 as a novel investigational cell therapy for Type 1 diabetes; Therapeutic Solutions International has filed a new patent and reported new data covering what they believe to be the first gene-modified, stem cell-derived, universal donor dendritic cell cancer immunotherapy; and Axol Bioscience have signed a merger agreement with Censo Biotechnologies. The news highlights: US FDA fast tracks a novel investigational cell therapy for Type 1 diabetes StemVacs-V™: patent filed for a novel cancer-resistant iPSC-derived dendritic cell immunotherapy Axol Bioscience and Censo Biotechnologies sign merger agreement   US FDA...